Skip to Content Facebook Feature Image

The Hackett Group® Establishes AI World Class Procurement Benchmarks

Business

The Hackett Group® Establishes AI World Class Procurement Benchmarks
Business

Business

The Hackett Group® Establishes AI World Class Procurement Benchmarks

2026-07-13 22:00 Last Updated At:22:10

MIAMI--(BUSINESS WIRE)--Jul 13, 2026--

The Hackett Group, Inc. (NASDAQ: HCKT), an ROI-led AI transformation firm, today announced AI World Class Procurement benchmarks – new research that quantifies how artificial intelligence (AI) is reshaping procurement performance and reveals a growing gap between organizations redesigning source-to-pay around AI and those that simply automate existing procurement activities.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713704676/en/

These new benchmarks build on The Hackett Group’s AI World Class research introduced in May, which identified performance advantages of up to 75% for organizations pursuing process-led AI transformation. The new procurement benchmarks show how those advantages emerge across critical procurement processes and where organizations can create measurable improvements in procurement return on investment (ROI), savings generation, supplier performance, and business value.

The research indicates that the next phase of AI adoption will be defined less by technology deployment and more by the business value procurement creates. As organizations face continued pressure to improve margins and strengthen supply resilience, chief procurement officers are increasingly expected to accelerate savings, strengthen supplier performance, improve compliance and reduce enterprise risk with leaner teams.

“Most organizations are still trying to justify AI investments one use case at a time,” said Tim Yoo, principal and Procurement Transformation practice leader at The Hackett Group ®. “Our research shows the greatest returns come when organizations redesign procurement processes with AI as a key enabler, allowing better decisions to build value throughout the end-to-end process.”

The new benchmarks span critical procurement processes, including sourcing, supplier management, purchasing, purchase-to-pay and supplier performance. AI World Class Procurement benchmarks quantify where process-led AI transformation can create the greatest value and establish future-state performance standards across the procurement function.

Purchase-to-pay demonstrates how AI creates compounding value. Better supplier intelligence, sourcing decisions, and increasingly autonomous transaction processing reinforce one another throughout the procurement process to increase savings, supplier performance, compliance and ROI.

The performance impact is significant. AI World Class organizations generate up to 3.7X greater procurement ROI and 3X greater savings impact. AI World Class modeling also shows purchase-to-pay process costs can decline by up to 80%, while staffing requirements can decrease by up to 81%, creating capacity for supplier strategy, sourcing optimization and higher-value commercial decision-making.

Competitive bidding increases by 97% alongside 42% greater supplier concentration, improving sourcing outcomes before a purchase order is ever created. Guided buying and catalog adoption improved by 110%, reducing maverick spend leakage by 69%. As purchasing quality improves, invoice errors decline by 76%, invoice processing accelerates by 74% and transaction execution becomes increasingly autonomous.

The impact becomes even more visible as procurement organizations redirect capacity from administration to supplier strategy. Increasingly autonomous execution frees procurement professionals to spend more time strengthening supplier relationships, optimizing sourcing strategies and pursuing commercial opportunities with the greatest potential.

“Procurement creates the greatest value before an order is placed,” said Jeff Gilkerson, principal at The Hackett Group ®. “AI gives procurement teams the capacity to spend less time administering transactions and more time making better supplier and commercial decisions that strengthen enterprise performance.”

While purchase-to-pay provides a clear illustration of the opportunity, similar patterns emerge across the broader AI World Class benchmark portfolio. The benchmarks span 16 end-to-end enterprise processes and identify where process reinvention can unlock the greatest gains in cost, productivity, speed and business performance. The most significant value is created when organizations redesign how work flows across an entire process enabled by AI rather than focusing on isolated automation opportunities.

The AI World Class benchmarks are grounded in more than 30 years of benchmark data, process intelligence and transformation experience drawn from leading global organizations, including 98% of the Dow Jones Global Titans, 97% of the Dow Jones Industrials and 90% of the Fortune 100.

The AI World Class Procurement benchmarks are available exclusively through The Hackett Group ®. Download the AI World Class Procurement report to learn how process-led AI transformation is creating a growing procurement performance gap and where organizations can capture the greatest procurement value.

About The Hackett Group®

The Hackett Group, Inc. (NASDAQ: HCKT) is an ROI-led, AI enterprise transformation firm that helps clients enable AI world-class performance. Its experts and engineers leverage proprietary AI delivery platforms – Hackett AI XPLR™, ZBrain™, XT™, AIXelerator™ and AskHackett™ – to accelerate and enhance the delivery of the company’s solutions and services.

The AI platforms are powered by the company’s domain-specific Hackett Solution Language Model informed by Hackett Process and Performance Intelligence – including Digital World Class ® benchmark metrics, best-practice process flows and service delivery model solution frameworks, which accelerate and enhance the delivery of its services. The Hackett Group’s proprietary insights are based on benchmarking results from leading global organizations, including 98% of Dow Jones Global Titans, 97% of the Dow Jones Industrials and 90% of the Fortune 100. Visit www.thehackettgroup.com

Trademarks

The Hackett Group ®, quadrant logo, and Digital World Class ® are the registered marks of The Hackett Group ®.

Cautionary Statement Regarding “Forward-Looking” Statements

This release contains “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements including without limitation, words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” or other similar phrases or variations of such words or similar expressions indicating, present or future anticipated or expected occurrences or outcomes are intended to identify such forward-looking statements. Forward-looking statements are not statements of historical fact and involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statements. Factors that may impact such forward-looking statements include without limitation, the ability of The Hackett Group ® to effectively market its digital transformation services, our ability to transition our capabilities to support generative artificial intelligence (AI)-related consulting services and solutions and other consulting services, our ability to effectively integrate acquisitions into our operations, our ability to manage joint ventures and successfully cooperate with our joint venture partners, competition from other consulting and technology companies that may have or develop in the future, similar offerings, the commercial viability of The Hackett Group ® and its services as well as other risk detailed in The Hackett Group’s reports filed with the United States Securities and Exchange Commission. The Hackett Group ® does not undertake any duty to update this release or any forward-looking statements contained herein.

Purchase-to-pay provides one of the clearest examples of how AI creates enterprise value within procurement. Improvements in supplier intelligence, sourcing effectiveness, purchasing efficiency and transaction processing reinforce one another. Better decisions upstream reduce work downstream, improving supplier performance and strengthening procurement ROI throughout the process. While many organizations focus on automating individual procurement activities, AI World Class reveals a larger opportunity: redesigning the end-to-end purchase-to-pay process around AI. AI World Class modeling shows purchase-to-pay process costs can decline by up to 80%, while staffing requirements per billion dollars of spend can decline by up to 81%. This creates the opportunity to shift procurement capacity toward supplier strategy, sourcing optimization and commercial decision-making.

Purchase-to-pay provides one of the clearest examples of how AI creates enterprise value within procurement. Improvements in supplier intelligence, sourcing effectiveness, purchasing efficiency and transaction processing reinforce one another. Better decisions upstream reduce work downstream, improving supplier performance and strengthening procurement ROI throughout the process. While many organizations focus on automating individual procurement activities, AI World Class reveals a larger opportunity: redesigning the end-to-end purchase-to-pay process around AI. AI World Class modeling shows purchase-to-pay process costs can decline by up to 80%, while staffing requirements per billion dollars of spend can decline by up to 81%. This creates the opportunity to shift procurement capacity toward supplier strategy, sourcing optimization and commercial decision-making.

BOCA RATON, Fla.--(BUSINESS WIRE)--Jul 13, 2026--

Massive Bio, a technology company that uses artificial intelligence to help cancer patients identify clinical trials for which they may be eligible, today announced a new partnership with Sequence Me Now (SMN), a nonprofit patient advocacy organization dedicated to helping cancer patients access genomic sequencing and personalized medicine.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713305414/en/

Through the partnership, Massive Bio is featured on the "Find a Trial" page of Sequence Me Now's website, the fourth step of the nonprofit's Sequence Code, a five-step patient playbook founded by Bryce Olson, a cancer patient who used his own genomic sequencing results to outlast an initial 21-month prognosis by nine years. Massive Bio, in turn, has built a dedicated landing page for Sequence Me Now patients, where they can complete an intake form to explore what clinical trials may be available to them based on their diagnosis and biomarker profile.

Sequence Me Now's mission, “Power to the Patient,” is to further the personalized medicine movement Bryce Olson started by giving patients the tools and vocabulary to demand biomarker testing, decode their results, and pursue the treatments and trials that match their profile. Massive Bio's clinical-trial matching technology is a natural next step for patients who complete SMN's Sequence Code and are ready to find a matching trial.

“As a practicing oncologist, I have seen how often patients get their genomic sequencing results back and are not sure what to do next,” said Arturo Loaiza-Bonilla, MD, Co-Founder and Chief Medical AI Officer of Massive Bio. “Sequence Me Now gives patients the courage to demand that testing in the first place. Once they have their results, our platform helps translate that data into real clinical trial options, matched to their specific biomarkers.”

"The Sequence Code is not just Bryce's story. It is a curated roadmap for every patient who refuses to accept that they have run out of options," said Hans George, Chair of the Board of Directors for Sequence Me Now. "Our mission is to ensure every patient has the knowledge, tools, and confidence to advocate for the care they deserve."

Sequence Me Now has spent years giving patients the tools and the vocabulary to ask the right questions about their own care,” said Toygun Rauf Onaran, SVP, U.S. Provider Engagement and Partnerships at Massive Bio. “We are proud to partner with them and to give their patients a clear next step toward finding a clinical trial that may be right for them.”

About Massive Bio

Massive Bio, co-founded by Selin Kurnaz, Arturo Loaiza-Bonilla, and Çağatay Çulcuoğlu, transforms the pharmaceutical value chain with AI-driven solutions. As an AI-enabled real-world data company, Massive Bio streamlines patient journeys, improves access to cutting-edge treatments, and optimizes clinical trial operations across 17 countries. A recipient of the DiMe Seal, the Digital Medicine Society's independent quality certification covering clinical evidence, privacy, security, and usability, Massive Bio is listed in the CMS Medicare App Library, connecting its platform to more than 68 million Medicare beneficiaries. A founding member of the CancerX public-private partnership and participant in the White House Cancer Moonshot initiative, the company continues to lead the way in ethical AI and data-driven innovation.

For more information, visit www.massivebio.com.

About Sequence Me Now

Sequence Me Now is a 501(c)(3) nonprofit founded in 2018 in Portland, Oregon, dedicated to fighting cancer differently, with data. Its mission, Power to the Patient, furthers the personalized medicine movement started by founder Bryce Olson by providing a hub of curated self-advocacy tools and resources, for patients, by patients. Its vision, Personalized Medicine for All, is to bring personalized medicine to every patient, including in community hospitals and rural areas, and make cancer survivable. Its flagship program, the Sequence Code, is a free, five-step patient playbook, the same steps Bryce Olson walked when standard treatment failed, a path that outlasted his initial 21-month prognosis by nine years.

Learn more at sequencemenow.org.

Massive Bio Announces Partnership with Sequence Me Now to Help Cancer Patients Access Clinical Trials

Massive Bio Announces Partnership with Sequence Me Now to Help Cancer Patients Access Clinical Trials

Recommended Articles